Covered recipient · General Payments record
VU Q PHAN
Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2024 · Entire year
$8,596.02
277 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2024 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $6,555.18 | 272 |
| Consulting Fee | $1,650.00 | 1 |
| Education | $390.84 | 4 |
By paying entity
PY2024 · entire year · sorted by reported total
Page 6 of 6; records 251–277 of 277 matching records. This page contains 27 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
VU Q PHAN
NPI 1831247667 · CMS profile ID 37451
Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology
LOS ALAMITOS, CA
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 6 of 6; records 251–277 of 277 matching records. This page contains 27 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1831247667?year=2024&recipient=provider&page=6#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- VU Q PHAN, NPI 1831247667, CMS profile ID 37451. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 6 of 6; records 251–277 of 277 matching records. This page contains 27 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1831247667?year=2024&recipient=provider&page=6#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- APA 7
- IndustryPayments. (2026). VU Q PHAN, NPI 1831247667, CMS profile ID 37451. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 6 of 6; records 251–277 of 277 matching records. This page contains 27 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1831247667?year=2024&recipient=provider&page=6#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- Bluebook
- VU Q PHAN, NPI 1831247667, CMS profile ID 37451, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 6 of 6; records 251–277 of 277 matching records. This page contains 27 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1831247667?year=2024&recipient=provider&page=6#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2024
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30
277 matching records · $8,596.02 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 251–277 of 277.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Merck Sharp & Dohme LLC | $32.68 | 01/31/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1141761113 | CMS |
| PFIZER INC. | $29.67 | 01/30/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1131294854 | CMS |
| Celgene Corporation | $11.41 | 01/29/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1101122192 | CMS |
| ImmunoGen, Inc. | $14.84 | 01/26/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1099941755 | CMS |
| Merck Sharp & Dohme LLC | $26.39 | 01/26/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1141760931 | CMS |
| PharmaEssentia USA Corporation | $29.20 | 01/25/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1137310776 | CMS |
| Incyte Corporation | $15.00 | 01/24/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1141299025 | CMS |
| Janssen Biotech, Inc. | $12.51 | 01/24/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1078305650 | CMS |
| GlaxoSmithKline, LLC. | $17.99 | 01/23/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1116311469 | CMS |
| PUMA BIOTECHNOLOGY, INC. | $20.65 | 01/22/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1113856383 | CMS |
| PFIZER INC. | $17.94 | 01/19/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1130894103 | CMS |
| Astellas Pharma US Inc | $17.85 | 01/18/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1139289340 | CMS |
| Organon Llc | $14.29 | 01/18/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1136239004 | CMS |
| Lilly USA, LLC | $34.71 | 01/17/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1135440979 | CMS |
| Tempus AI, Inc | $29.50 | 01/16/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1150171969 | CMS |
| Merck Sharp & Dohme LLC | $18.22 | 01/15/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1141761101 | CMS |
| Celgene Corporation | $23.44 | 01/12/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1101122186 | CMS |
| Spectrum Pharmaceuticals Inc. | $28.52 | 01/11/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1150656213 | CMS |
| AstraZeneca Pharmaceuticals LP | $23.47 | 01/10/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1104230479 | CMS |
| AstraZeneca Pharmaceuticals LP | $20.50 | 01/09/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1104618524 | CMS |
| Merck Sharp & Dohme LLC | $32.11 | 01/09/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1141761117 | CMS |
| Genmab U.S., Inc. | $30.94 | 01/07/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1126833303 | CMS |
| Regeneron Healthcare Solutions, Inc. | $33.76 | 01/05/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1114137090 | CMS |
| Cardinal Health 110 LLC | $1,650.00 | 01/04/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1100223261 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $30.15 | 01/04/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1144965141 | CMS |
| Dendreon Pharmaceuticals LLC | $29.84 | 01/02/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1149322157 | CMS |
| Dendreon Pharmaceuticals LLC | $28.66 | 01/02/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1149322159 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $1,939,793.98 | 75 |
| PY2024 | Principal investigator | $531,983.19 | 16 |
| PY2023 | Recipient | $291.47 | 2 |
| PY2023 | Principal investigator | $145,754.35 | 29 |
| PY2022 | Recipient | $2,011.00 | 2 |
| PY2022 | Principal investigator | $100,356.80 | 9 |
| PY2021 | Principal investigator | $79,408.52 | 2 |
| PY2020 | Principal investigator | $33,128.52 | 2 |
| PY2019 | Principal investigator | $41.72 | 1 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
75 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Janssen Research & Development, LLC | $124,764.90 | 12/26/2025 | Non-covered Recipient Entity CANCER AND BLOOD RESEARCH CENTER LL | A Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC and Lenalidomide (Tec-DR) versus Daratumumab SC, Lenalidomide, and Dexamethasone (DRd) in Participants with Newly Diagnosed Multiple Myeloma Who are Either Ineligible or not Intended for Autologous Stem Cell Transplant as Initial Therapy. | No dispute reported | 06/30/2026 | 1175436392 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,689.78 | 12/11/2025 | Non-covered Recipient Entity CANCER AND BLOOD RESEARCH CENTER LLC | A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184274574 |
| Principal investigator 1 | Janssen Research & Development, LLC | $8,057.00 | 12/04/2025 | Non-covered Recipient Entity CANCER AND BLOOD RESEARCH CENTER LL | A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer | No dispute reported | 06/30/2026 | 1175436398 |
| Principal investigator 1 | Janssen Research & Development, LLC | $6,800.00 | 12/04/2025 | Non-covered Recipient Entity CANCER AND BLOOD RESEARCH CENTER LL | A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer | No dispute reported | 06/30/2026 | 1175436809 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $7,894.00 | 12/03/2025 | Non-covered Recipient Entity Cancer And Blood Specialty Clinic | A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) vs Epoetin Alfa for the Treatment of Anemia Due to Revised International Prognostic Scoring System (IPSS-R) Very Low, Low, or Intermediate Risk Myelodysplastic Syndrome (MDS) in Erythropoiesis-Stimulating Agent (ESA)-naive Participants who are Non-Transfusion Dependent (NTD): The ELEMENT-MDS Trial | No dispute reported | 06/30/2026 | 1235998450 |
| Principal investigator 1 | Janssen Research & Development, LLC | $86,087.00 | 12/01/2025 | Non-covered Recipient Entity CANCER AND BLOOD RESEARCH CENTER LL | A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer | No dispute reported | 06/30/2026 | 1175436668 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $25,489.98 | 11/25/2025 | Non-covered Recipient Entity CANCER AND BLOOD RESEARCH CENTER LLC | A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184264493 |
| Principal investigator 1 | Amgen Inc. | $4,000.00 | 11/22/2025 | Non-covered Recipient Entity TRANSLATIONAL RESEARCH IN ONCOLOGY US INC | A Phase 1b/3 Study of Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab Alone in Subjects With Previously Untreated Advanced Gastric and Gastroesophageal Junction Cancer With FGFR2b Overexpression | No dispute reported | 06/30/2026 | 1246649880 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $22,850.00 | 11/21/2025 | Non-covered Recipient Entity Cancer And Blood Specialty Clinic | A Phase 3, Two-part, Randomized, Open-label, Adaptive Study Comparing BMS-986365 versus Investigators Choice of Therapy Comprising Either Docetaxel or Second Androgen Receptor Pathway Inhibitor (ARPI), in Participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) - rechARge | No dispute reported | 06/30/2026 | 1235998448 |
| Principal investigator 1 | Janssen Research & Development, LLC | $12,330.00 | 11/07/2025 | Non-covered Recipient Entity CANCER AND BLOOD RESEARCH CENTER LL | A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer | No dispute reported | 06/30/2026 | 1175436649 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $15,041.22 | 11/07/2025 | Non-covered Recipient Entity CANCER AND BLOOD RESEARCH CENTER LLC | A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184258929 |
| Principal investigator 1 | Janssen Research & Development, LLC | $9,447.00 | 11/05/2025 | Non-covered Recipient Entity CANCER AND BLOOD RESEARCH CENTER LL | A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer | No dispute reported | 06/30/2026 | 1175436467 |
| Principal investigator 1 | Janssen Research & Development, LLC | $9,438.00 | 11/05/2025 | Non-covered Recipient Entity CANCER AND BLOOD RESEARCH CENTER LL | A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer | No dispute reported | 06/30/2026 | 1175436486 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,337.00 | 11/05/2025 | Non-covered Recipient Entity CANCER AND BLOOD RESEARCH CENTER LL | A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer | No dispute reported | 06/30/2026 | 1175436540 |
| Principal investigator 1 | Janssen Research & Development, LLC | $23,757.00 | 11/05/2025 | Non-covered Recipient Entity CANCER AND BLOOD RESEARCH CENTER LL | A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer | No dispute reported | 06/30/2026 | 1175436604 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,257.00 | 11/05/2025 | Non-covered Recipient Entity CANCER AND BLOOD RESEARCH CENTER LL | A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer | No dispute reported | 06/30/2026 | 1175436663 |
| Principal investigator 1 | Janssen Research & Development, LLC | $17,528.70 | 11/03/2025 | Non-covered Recipient Entity CANCER AND BLOOD RESEARCH CENTER LL | A Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC and Lenalidomide (Tec-DR) versus Daratumumab SC, Lenalidomide, and Dexamethasone (DRd) in Participants with Newly Diagnosed Multiple Myeloma Who are Either Ineligible or not Intended for Autologous Stem Cell Transplant as Initial Therapy. | No dispute reported | 06/30/2026 | 1175436627 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 10/29/2025 | Non-covered Recipient Entity CANCER AND BLOOD RESEARCH CENTER LLC | A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184253628 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $446.85 | 10/29/2025 | Non-covered Recipient Entity CANCER AND BLOOD RESEARCH CENTER LLC | A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184253630 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $15,056.55 | 10/29/2025 | Non-covered Recipient Entity CANCER AND BLOOD RESEARCH CENTER LLC | A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184253632 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $14,540.85 | 10/29/2025 | Non-covered Recipient Entity CANCER AND BLOOD RESEARCH CENTER LLC | A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184253634 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $743.85 | 10/29/2025 | Non-covered Recipient Entity CANCER AND BLOOD RESEARCH CENTER LLC | A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184253636 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $8,772.06 | 10/23/2025 | Non-covered Recipient Entity CANCER AND BLOOD RESEARCH CENTER LLC | A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184252576 |
| Principal investigator 1 | Celgene Corporation | $28,000.00 | 10/22/2025 | Non-covered Recipient Entity Cancer And Blood Specialty Clinic | A Phase 3, Two-part, Randomized, Open-label, Adaptive Study Comparing BMS-986365 versus Investigators Choice of Therapy Comprising Either Docetaxel or Second Androgen Receptor Pathway Inhibitor (ARPI), in Participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) - rechARge | No dispute reported | 06/30/2026 | 1222305584 |
| Principal investigator 1 | Janssen Research & Development, LLC | $9,227.00 | 10/16/2025 | Non-covered Recipient Entity CANCER AND BLOOD RESEARCH CENTER LL | A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer | No dispute reported | 06/30/2026 | 1175436349 |
| Principal investigator 1 | Janssen Research & Development, LLC | $5,404.00 | 10/16/2025 | Non-covered Recipient Entity CANCER AND BLOOD RESEARCH CENTER LL | A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer | No dispute reported | 06/30/2026 | 1175436405 |
| Principal investigator 1 | Janssen Research & Development, LLC | $22,953.00 | 10/16/2025 | Non-covered Recipient Entity CANCER AND BLOOD RESEARCH CENTER LL | A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer | No dispute reported | 06/30/2026 | 1175436715 |
| Principal investigator 1 | Amgen Inc. | $30,218.50 | 10/03/2025 | Non-covered Recipient Entity CANCER AND BLOOD RESEARCH CENTER LLC | A Randomized, Double-Blind Study to Compare Efficacy, Pharmacokinetics, Safety, and Immunogenicity Between ABP 234 and Keytruda (Pembrolizumab) in Subjects With Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1246639859 |
| Principal investigator 1 | Janssen Research & Development, LLC | $30,650.62 | 09/29/2025 | Non-covered Recipient Entity CANCER AND BLOOD RESEARCH CENTER LL C | A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer | No dispute reported | 06/30/2026 | 1175436834 |
| Principal investigator 1 | Janssen Research & Development, LLC | $44,500.00 | 09/26/2025 | Non-covered Recipient Entity CANCER AND BLOOD RESEARCH CENTER LL C | A Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC and Lenalidomide (Tec-DR) versus Daratumumab SC, Lenalidomide, and Dexamethasone (DRd) in Participants with Newly Diagnosed Multiple Myeloma Who are Either Ineligible or | No dispute reported | 06/30/2026 | 1175436775 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $3,520.97 | 09/24/2025 | Non-covered Recipient Entity Cancer And Blood Specialty Clinic | A PHASE 3, TWO-STAGE, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY COMPARING MEZIGDOMIDE (CC-92480), BORTEZOMIB AND DEXAMETHASONE (MEZIVd) VERSUS POMALIDOMIDE, BORTEZOMIB AND DEXAMETHASONE (PVd) IN SUBJECTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): SUCCESSOR-1 | No dispute reported | 06/30/2026 | 1235998444 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,082.28 | 09/23/2025 | Non-covered Recipient Entity CANCER AND BLOOD RESEARCH CENTER LLC | A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184241614 |
| Principal investigator 1 | Janssen Research & Development, LLC | $9,723.00 | 09/19/2025 | Non-covered Recipient Entity CANCER AND BLOOD RESEARCH CENTER LL C | A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer | No dispute reported | 06/30/2026 | 1175436356 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $14,069.34 | 09/18/2025 | Non-covered Recipient Entity CANCER AND BLOOD RESEARCH CENTER LLC | A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184240448 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,830.83 | 09/12/2025 | Non-covered Recipient Entity CANCER AND BLOOD RESEARCH CENTER LLC | A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184236540 |
| Principal investigator 1 | PFIZER INC. | $1,519.00 | 09/02/2025 | Non-covered Recipient Entity TRANSLATIONAL RESEARCH IN ONCOLOGY | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228753872 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $9,015.06 | 08/26/2025 | Non-covered Recipient Entity CANCER AND BLOOD RESEARCH CENTER LLC | A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184230311 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,689.78 | 08/21/2025 | Non-covered Recipient Entity CANCER AND BLOOD RESEARCH CENTER LLC | A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184229729 |
| Principal investigator 1 | Janssen Research & Development, LLC | $410.33 | 08/18/2025 | Non-covered Recipient Entity CANCER AND BLOOD RESEARCH CENTER LL C | A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer | No dispute reported | 06/30/2026 | 1175436343 |
| Principal investigator 1 | Janssen Research & Development, LLC | $37,374.24 | 08/18/2025 | Non-covered Recipient Entity CANCER AND BLOOD RESEARCH CENTER LL C | A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer | No dispute reported | 06/30/2026 | 1175436656 |
| Principal investigator 1 | Janssen Research & Development, LLC | $9,834.00 | 08/18/2025 | Non-covered Recipient Entity CANCER AND BLOOD RESEARCH CENTER LL C | A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer | No dispute reported | 06/30/2026 | 1175436780 |
| Principal investigator 1 | PFIZER INC. | $10,269.00 | 08/18/2025 | Non-covered Recipient Entity TRANSLATIONAL RESEARCH IN ONCOLOGY | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228766319 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $13,704.84 | 08/14/2025 | Non-covered Recipient Entity CANCER AND BLOOD RESEARCH CENTER LLC | A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184228301 |
| Principal investigator 1 | Janssen Research & Development, LLC | $38,523.00 | 08/11/2025 | Non-covered Recipient Entity CANCER AND BLOOD RESEARCH CENTER LL C | A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer | No dispute reported | 06/30/2026 | 1175436704 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $16,900.17 | 08/07/2025 | Non-covered Recipient Entity CANCER AND BLOOD RESEARCH CENTER LLC | A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184226123 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,647.00 | 08/04/2025 | Non-covered Recipient Entity CANCER AND BLOOD RESEARCH CENTER LL C | A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer | No dispute reported | 06/30/2026 | 1175436621 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,507.53 | 07/17/2025 | Non-covered Recipient Entity CANCER AND BLOOD RESEARCH CENTER LLC | A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184217040 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $49,160.41 | 07/10/2025 | Non-covered Recipient Entity CANCER AND BLOOD RESEARCH CENTER LLC | A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184214342 |
| Principal investigator 1 | Janssen Research & Development, LLC | $45,374.00 | 07/04/2025 | Non-covered Recipient Entity CANCER AND BLOOD RESEARCH CENTER LL C | A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer | No dispute reported | 06/30/2026 | 1175436742 |
| Principal investigator 1 | Janssen Research & Development, LLC | $9,399.00 | 06/30/2025 | Non-covered Recipient Entity CANCER AND BLOOD RESEARCH CENTER LL C | A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer | No dispute reported | 06/30/2026 | 1175436413 |
| Principal investigator 1 | Janssen Research & Development, LLC | $12,330.00 | 06/30/2025 | Non-covered Recipient Entity CANCER AND BLOOD RESEARCH CENTER LL C | A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer | No dispute reported | 06/30/2026 | 1175436526 |
| Principal investigator 1 | Janssen Research & Development, LLC | $12,330.00 | 06/30/2025 | Non-covered Recipient Entity CANCER AND BLOOD RESEARCH CENTER LL C | A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer | No dispute reported | 06/30/2026 | 1175436768 |
| Principal investigator 1 | Janssen Research & Development, LLC | $5,530.00 | 06/30/2025 | Non-covered Recipient Entity CANCER AND BLOOD RESEARCH CENTER LL C | A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer | No dispute reported | 06/30/2026 | 1175436855 |
| Principal investigator 1 | Janssen Research & Development, LLC | $7,564.00 | 06/16/2025 | Non-covered Recipient Entity CANCER AND BLOOD RESEARCH CENTER LL C | A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer | No dispute reported | 06/30/2026 | 1175436430 |
| Principal investigator 1 | Janssen Research & Development, LLC | $10,392.00 | 06/16/2025 | Non-covered Recipient Entity CANCER AND BLOOD RESEARCH CENTER LL C | A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer | No dispute reported | 06/30/2026 | 1175436849 |
| Principal investigator 1 | PFIZER INC. | $6,261.00 | 06/16/2025 | Non-covered Recipient Entity TRANSLATIONAL RESEARCH IN ONCOLOGY | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228776839 |
| Principal investigator 1 | Janssen Research & Development, LLC | $21,392.00 | 06/03/2025 | Non-covered Recipient Entity CANCER AND BLOOD RESEARCH CENTER LL C | A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer | No dispute reported | 06/30/2026 | 1175436761 |
| Principal investigator 1 | Celgene Corporation | $18,808.00 | 05/12/2025 | Non-covered Recipient Entity Cancer And Blood Specialty Clinic | A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) vs Epoetin Alfa for the Treatment of Anemia Due to Revised International Prognostic Scoring System (IPSS-R) Very Low, Low, or Intermediate Risk Myelodysplastic Syndrome (MDS) in Erythropoiesis-Stimulating Agent (ESA)-naive Participants who are Non-Transfusion Dependent (NTD): The ELEMENT-MDS Trial | No dispute reported | 06/30/2026 | 1222305634 |
| Principal investigator 1 | PFIZER INC. | $1,519.00 | 05/05/2025 | Non-covered Recipient Entity TRANSLATIONAL RESEARCH IN ONCOLOGY | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228763271 |
| Principal investigator 1 | Janssen Research & Development, LLC | $24,725.00 | 05/02/2025 | Non-covered Recipient Entity CANCER AND BLOOD RESEARCH CENTER LL C | A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer | No dispute reported | 06/30/2026 | 1175436423 |
| Principal investigator 1 | Janssen Research & Development, LLC | $26,509.00 | 04/11/2025 | Non-covered Recipient Entity CANCER AND BLOOD RESEARCH CENTER LL C | A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer | No dispute reported | 06/30/2026 | 1175436435 |
| Principal investigator 1 | Amgen Inc. | $23,163.79 | 03/27/2025 | Non-covered Recipient Entity CANCER AND BLOOD SPECIALTY CLINIC | A Randomized, Double-Blind Study Evaluating the Efficacy, Safety, and Immunogenicity of ABP 206 Compared With OPDIVO (Nivolumab) in Subjects With Treatment-Nave Unresectable or Metastatic Melanoma | No dispute reported | 06/30/2026 | 1246639863 |
| Principal investigator 1 | PFIZER INC. | $14,829.00 | 03/24/2025 | Non-covered Recipient Entity TRANSLATIONAL RESEARCH IN ONCOLOGY | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228796817 |
| Principal investigator 1 | Celgene Corporation | $46,057.00 | 03/19/2025 | Non-covered Recipient Entity Cancer And Blood Specialty Clinic | A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) vs Epoetin Alfa for the Treatment of Anemia Due to Revised International Prognostic Scoring System (IPSS-R) Very Low, Low, or Intermediate Risk Myelodysplastic Syndrome (MDS) in Erythropoiesis-Stimulating Agent (ESA)-naive Participants who are Non-Transfusion Dependent (NTD): The ELEMENT-MDS Trial | No dispute reported | 06/30/2026 | 1222305582 |
| Principal investigator 1 | Janssen Research & Development, LLC | $44,500.00 | 03/10/2025 | Non-covered Recipient Entity CANCER AND BLOOD RESEARCH CENTER LL C | A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer | No dispute reported | 06/30/2026 | 1175436508 |
| Principal investigator 1 | PFIZER INC. | $25,496.92 | 03/04/2025 | Non-covered Recipient Entity CANCER AND BLOOD RESEARCH | A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228781475 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $40,820.00 | 02/26/2025 | Non-covered Recipient Entity Cancer And Blood Specialty Clinic | Phase 3b, Open-label study evaluating the efficacy and safety of luspatercept (BMS-986346/ACE-536) initiated at maximum approved dose in LR-MDS with IPSS-R very low, low or intermediate risk who require RBC transfusions | No dispute reported | 06/30/2026 | 1235998446 |
| Principal investigator 1 | PFIZER INC. | $1,519.00 | 02/24/2025 | Non-covered Recipient Entity TRANSLATIONAL RESEARCH IN ONCOLOGY | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228797967 |
| Principal investigator 1 | Amgen Inc. | $1,492.00 | 02/21/2025 | Non-covered Recipient Entity CANCER AND BLOOD SPECIALTY CLINIC | A Phase 1b/3 Study of Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab Alone in Subjects With Previously Untreated Advanced Gastric and Gastroesophageal Junction Cancer With FGFR2b Overexpression | No dispute reported | 06/30/2026 | 1246639861 |
| Principal investigator 1 | PFIZER INC. | $8,348.00 | 02/10/2025 | Non-covered Recipient Entity TRANSLATIONAL RESEARCH IN ONCOLOGY | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228793917 |
| Principal investigator 1 | Amgen Inc. | $14.70 | 02/01/2025 | Non-covered Recipient Entity CANCER AND BLOOD SPECIALTY CLINIC | Phase 3 Multicenter, Randomized, Open-label, Active-controlled Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb for Treatment-nave Subjects With Metastatic Colorectal Cancer With KRAS p.G12C Mutation (CodeBreaK 301) | No dispute reported | 06/30/2026 | 1246639865 |
| Principal investigator 1 | Amgen Inc. | $23,496.00 | 01/29/2025 | Non-covered Recipient Entity CANCER AND BLOOD RESEARCH CENTER LLC | A Randomized, Double-blind Study Evaluating Pharmacokinetic Similarity of ABP 206 Compared With OPDIVO (Nivolumab) in Resected Stage III or Stage IV Melanoma Subjects in the Adjuvant Setting | No dispute reported | 06/30/2026 | 1246639855 |
| Principal investigator 1 | AstraZeneca UK Limited | $92,349.05 | 01/29/2025 | Non-covered Recipient Entity CANCER AND BLOOD RESEARCH CENTER LLC | A Phase III,Open label,Randomised,Multicentre Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Without Actionable Genomic Alterations,and Whose Disease Has Progressed On or After Prior Anti PD 1 Therapy and Platinum based Chemotherapy LATIFY | No dispute reported | 06/30/2026 | 1185537615 |
| Principal investigator 1 | Amgen Inc. | $129,783.63 | 01/16/2025 | Non-covered Recipient Entity CANCER AND BLOOD RESEARCH CENTER LLC | A Randomized, Double-Blind Study Evaluating the Efficacy, Safety, and Immunogenicity of ABP 206 Compared With OPDIVO (Nivolumab) in Subjects With Treatment-Nave Unresectable or Metastatic Melanoma | No dispute reported | 06/30/2026 | 1246639857 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $459,629.25 | 01/02/2025 | Non-covered Recipient Entity CANCER AND BLOOD RESEARCH CENTER LLC | a phase 3b,randomized,multicenter,open label study to assess the efficacy of durvalumab plus tremelimumab versus pembrolizumab in combination with platinum based chemotherapy for first line treatment in mtastatic non small cell lung cancer patients with non squamous histology who have mutations and or co mutations in skt11,keap1,or kras triton | No dispute reported | 06/30/2026 | 1185537613 |